Effect of Mukitake mushroom (Panellus serotinus) on the pathogenesis of lipid abnormalities in obese, diabetic ob/ob mice

Lipids in Health and Disease

Volumn 12, Issue 1, 2013, Pages

  Inoue, Nao ^a,b   Inafuku, Masashi ^a,c   Shirouchi, Bungo ^a,d   Nagao, Koji ^a   Yanagita, Teruyoshi ^a,e  

^a SAGA UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e NISHIKYUSHU UNIVERSITY   (Japan)

Author keywords

Atherogenic index; Nonalcoholic fatty acid disease; ob ob mice; Panellus serotinus

Indexed keywords

LEPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; FEEDING; HEPATOMEGALY; HYPERLIPIDEMIA; LIPID STORAGE; LIPOGENESIS; LIVER INJURY; MALE; METABOLIC DISORDER; MOUSE; MUSHROOM; NONHUMAN; OBESITY; PANELLUS SEROTINUS; PATHOGENESIS;

AGARICALES; ANIMALS; CARNITINE O-PALMITOYLTRANSFERASE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS; FATTY ACID SYNTHETASE COMPLEX; FOOD, FORMULATED; FRUITING BODIES, FUNGAL; GLUCOSEPHOSPHATE DEHYDROGENASE; HEPATOMEGALY; HYPERLIPIDEMIAS; LEPTIN; LIPID METABOLISM; MALE; MICE; MICE, KNOCKOUT; MICE, OBESE; OBESITY; PHOSPHATIDATE PHOSPHATASE; POWDERS; TRIGLYCERIDES;

BASIDIOMYCOTA; MUS; SARCOMYXA SEROTINA;

EID: 84873591324     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-12-18     Document Type: Article

References (30)

1. Functional properties of edible mushrooms. Chang R, Nutr Rev 1996 54 91 93 9110582
2. Medical mushrooms as a source of antitumor and immunomodulating polysaccharides. Wasser SP, Appl Microbiol Biotechnol 2002 60 258 274 10.1007/s00253-002-1076-7 12436306
3. Effect of hatakeshimeji (Lyophyllum decastes Sing.) mushroom on serum lipid levels in rats. Ukawa Y, Furuichi Y, Kokean Y, Nishii T, Hisamatsu M, J Nutr Sci Vitaminol 2002 8 73 76 (Pubitemid 34288928)
4. Medical mushroom modulators of molecular targets as cancer therpeutics. Zaidman B-Z, Yassin M, Mahajna J, Wasser SP, Appl Microbiol Biotechnol 2005 67 453 468 10.1007/s00253-004-1787-z 15726350 (Pubitemid 40909591)
5. Protection against D-galactosamine-induced acute liver injury by oral administration of extracts from lentinus edodes mycelia. Watanabe A, Kobayashi M, Hayashi S, Kodama D, Isoda K, Kondoh M, Kawase M, Tamesada M, Yagi K, Biol Pharm Bull 2006 29 1651 1654 10.1248/bpb.29.1651 16880621 (Pubitemid 44166368)
6. Oral administration of the extract from Hatakeshimeji (Lyophyllum decastes Sing.) mushroom inhibits the development of atopic dermatitis-like skin lesions in NC/Nga mice. Ukawa Y, Izumi Y, Ohbuchi T, Takahashi T, Ikemizu S, Kojima Y, J Nutr Sci Vitaminol 2007 53 293 196 10.3177/jnsv.53.293 17874836 (Pubitemid 47217228)
7. Simple equipment cultivation of Panellus serotinus. Nagamori N, Kyushu J Forrest Res 2007 60 146 148
8. Regional adiposity and morbidity. Kissebah AH, Krakower GR, Physiol Rev 1994 74 761 811 7938225 (Pubitemid 24328939)
9. Obesity: epidemiology and clinical aspects. Formiguera X, Canton A, Best Pract Res Clin Gastroenterol 2004 18 1125 1146 15561643 (Pubitemid 39517697)
10. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y, J Gastroenterol Hepatol 2007 22 1086 1091 10.1111/j.1440-1746.2006.04781.x 17608855 (Pubitemid 47019857)
11. Fat and the liver-a molecular overview. Harrison SA, Diehl AM, Semin Gastrointest Dis 2002 13 3 16 11944631 (Pubitemid 34262947)
12. Diabetes mellitus, obesity, and hepatic steatosis. Youssef W, McCullough AJ, Semin Gastrointest Dis 2002 13 17 30 11944630 (Pubitemid 34262948)
13. Bioactive lipids in metabolic syndrome. Nagao K, Yanagita T, Prog Lipid Res 2008 47 127 146 10.1016/j.plipres.2007.12.002 18177744
14. Diabetes, a new mutation in the mouse. Hummel KP, Dickie MM, Coleman DL, Science 1966 153 1127 1128 10.1126/science.153.3740.1127 5918576
15. Positional cloning of the mouse obese gene and its human homologue. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM, Nature 1994 372 425 432 10.1038/372425a0 7984236 (Pubitemid 24365442)
16. Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet. Trak-Smayra V, Paradis V, Massart J, Nasser S, Jebara V, Fromenty B, Int J Exp Pathol 2011 92 413 421 10.1111/j.1365-2613.2011. 00793.x 22118645
17. Mukitake mushroom (Panellus serotinus) alleviates nonalcoholic fatty liver disease through the suppression of monocyte chemoattractant protein-1 production in db/db mice. Nagao K, Inoue N, Inafuku M, Shirouchi B, Morooka T, Nomura S, Nagamori N, Yanagita T, J Nutr Biochem 2010 21 418 423 10.1016/j.jnutbio.2009.01.021 19423319
18. Protective effects of fractional extracts from Panellus serotinus on nonalcoholic fatty liver disease in obese, diabetic db/db mic. Inafuku M, Nagao K, Nomura S, Shirouchi B, Inoue N, Nagamori N, Nakayama H, Toda T, Yanagita T, Br J Nutr 2012 107 639 646 10.1017/S0007114511003485 21787451
19. Report of the American institute of nutrition ad hoc committee on standards for nutritional studies. American Institute of Nutrition, J Nutr 1977 107 1340 1348 874577
20. Short-term feeding of conjugated linoleic acid does not induce hepatic steatosis in C57BL/6J mice. Wang YM, Nagao K, Ujino Y, Sakata K, Higa K, Inoue N, Yanagita T, J Nutr Sci Vitaminol 2005 51 440 444 10.3177/jnsv.51.440 16521704 (Pubitemid 43151732)
21. Dietary phosphatidylinositol prevents the development of nonalcoholic fatty liver disease in Zucker (fa/fa) rats. Shirouchi B, Nagao K, Inoue N, Furuya K, Koga S, Matsumoto H, Yanagita T, J Agric Food Chem 2008 56 2375 2379 10.1021/jf703578d 18324772 (Pubitemid 351570428)
22. Campest-5-en-3-one, an oxidized derivative of campesterol, activates PPARα, promotes energy consumption and reduces visceral fat deposition in rats. Ikeda I, Konno R, Shimizu T, Ide T, Takahashi N, Kawada T, Nagao K, Inoue N, Yanagita T, Hamada T, Morinaga Y, Tomoyori H, Imaizumi K, Suzuki K, Biochim Biophys Acta 2006 1760 800 807 10.1016/j.bbagen.2006.02.017 16616424 (Pubitemid 44419349)
23. Isomer-specific anti-obese and hypolipidemic properties of conjugated linoleic acid in obese OLETF rats. Wang YM, Nagao K, Inoue N, Ujino Y, Shimada Y, Nagao T, Iwata T, Kamegai T, Yamauchi-Sato Y, Yanagita T, Biosci Biotechnol Biochem 2006 70 355 362 10.1271/bbb.70.355 16495650 (Pubitemid 43289415)
24. Effects of citrus auraptene (7-geranyloxycoumarin) on hepatic lipid metabolism in vitro and in vivo. Nagao K, Yamano N, Shirouchi B, Inoue N, Murakami S, Sasaki T, Yanagita T, J Agric Food Chem 2010 58 9028 9032 10.1021/jf1020329
25. Liver pathology and the metabolic syndrome X in severe obesity. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG, J Clin Endocrinol Metab 1999 84 1513 1517 10.1210/jc.84.5.1513 10323371 (Pubitemid 30644245)
26. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N, Diabetes 2001 50 1844 1850 10.2337/diabetes.50.8.1844 11473047 (Pubitemid 33641605)
27. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M, Hepatology 2003 37 917 923 10.1053/jhep.2003.50161 12668987 (Pubitemid 36397405)
28. Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Matsuzawa Y, Nat Clin Pract Cardiovasc Med 2006 3 35 42 10.1038/ncpcardio0380 16391616 (Pubitemid 43078211)
29. Steatohepatitis: a tale of two "hits"? Day CP, James OF, Gastroenterology 1998 114 842 845 10.1016/S0016-5085(98)70599-2 9547102 (Pubitemid 28160420)
30. Overproduction of very Low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Matsuzawa Y, Arterioscler Thromb Vasc Biol 2008 28 1225 1236 10.1161/ATVBAHA.107.160192 18565848